Document Detail


Treating heart failure with sildenafil.
MedLine Citation:
PMID:  19627292     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sildenafil is a selective inhibitor of type 5 phosphodiesterase, the main phosphodiesterase isoform responsible for hydrolysis of intracellular cyclic guanosine monophosphate in the pulmonary vasculature. It improves exercise capacity and quality of life in patients with systolic heart failure, especially in those who develop secondary pulmonary hypertension. It improves peak oxygen consumption, reduces minute ventilation/carbon dioxide output slope, and acts as a selective pulmonary vasodilator during rest and exercise in patients with heart failure and pulmonary hypertension. It improves flow-mediated maximal dilatation, ergoreflex on ventilation, and breathlessness both after 3 and 6 months of treatment. Sildenafil, by improving endothelial activity and muscle perfusion, improves signaling and ventilatory efficiencies, potentially indicating a novel approach in the therapeutic management of heart failure.
Authors:
Arnon Blum
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Congestive heart failure (Greenwich, Conn.)     Volume:  15     ISSN:  1751-7133     ISO Abbreviation:  Congest Heart Fail     Publication Date:    2009 Jul-Aug
Date Detail:
Created Date:  2009-07-24     Completed Date:  2009-10-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9714174     Medline TA:  Congest Heart Fail     Country:  United States    
Other Details:
Languages:  eng     Pagination:  181-5     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Baruch-Padeh Poria Medical Center, Lower Galilee, Israel. navablum@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Flow Velocity / drug effects
Heart Failure / complications,  drug therapy*
Hemodynamics / drug effects
Humans
Hypertension, Pulmonary / drug therapy,  etiology
Muscle, Smooth / drug effects
Oxygen Consumption / drug effects
Phosphodiesterase Inhibitors / therapeutic use*
Piperazines / therapeutic use*
Purines / therapeutic use
Quality of Life
Reflex / drug effects
Sulfones / therapeutic use*
Systole
Chemical
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 139755-83-2/sildenafil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of exercise training on 24-hour ambulatory blood pressure monitoring in heart failure patient...
Next Document:  Understanding heart failure with preserved ejection fraction: clinical importance and future outlook...